ICIs immunotherapy consisting of anti-CTLA4 and anti-PD1 has been shown to be effective in non-small cell lung cancers and oropharyngeal cancer, and the feasibility of applying immunotherapy to cervical cancer is receiving increasing attention and research51,52. This evidence concerns the gene CTLA4 and cervical carcinoma.